News | Artificial Intelligence | November 05, 2022

Guerbet announced an agreement with Merative, formalizing the termination of their collaboration signed in July 2018

Guerbet announced an agreement with Merative, formalizing the termination of their collaboration signed in July 2018.

Nov. 4, 2022 — Guerbet announced an agreement with Merative formalizing the termination of their collaboration initiated in July 2018. This partnership aimed to design, develop and market software solutions to help diagnose and monitor liver and prostate cancers. The termination follows Merative's strategic shift in how it delivers artificial intelligence within its imaging product portfolio.The new Asset Assignment and License Agreement grants Guerbet the ability and autonomy to pursue research and development, and plan for the market launch of artificial intelligence solutions. Assets developed during the partnership, including source code for application software, Artificial Intelligence algorithms and the associated intellectual property, are being transferred to Guerbet. The market potential remains unchanged and significant, and this Asset Assignment and License Agreement will transfer control over the remaining development work to Guerbet. Promising initial results have been obtained in 2022, particularly for the detection of liver lesions (presentation scheduled for the RSNA 2022 conference) and for the detection of prostate cancer (work presented at the ECR 2022 conference). The high quality of the work presented by Guerbet’s Artificial Intelligence research team also impressed the jury of the BPI France 2030 program, which has awarded the company €1 million in funding for its project aimed at early detection of pancreatic cancer, as recently announced. Numerous stakeholders have communicated their interest to the Group’s management in recent months, attesting to the business’ strong potential. Constructive discussions are currently also underway to set up new partnerships in order to accelerate the business roadmap and to facilitate the emergence of a national champion in the area of artificial intelligence for medical imaging.

For more information: www.guerbet.com

Find more RSNA22 coverage here 


Related Content

News | Digital Pathology

July 12, 2024 — AGFA HealthCare, a global leader in healthcare imaging management solutions, announced that Enterprise ...

Time July 12, 2024
arrow
News | Digital Pathology

July 12, 2024 — Diagnosing cancer and providing the personalized therapy it often requires, is a collaborative effort ...

Time July 12, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 12, 2024
arrow
Feature | Imaging Technology News - ITN

Be sure to check out the latest digital edition of Imaging Technology News (ITN), featuring the Mobile C-arm Systems ...

Time July 11, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
News | Artificial Intelligence

July 11, 2024 — Artificial Intelligence (AI) tools can play a key role in medical imaging if radiologists trust in their ...

Time July 11, 2024
arrow
Feature | Radiology Business | By Christine Book

Across the healthcare industry, and, notably, throughout the radiology community in just the past few years, the focus ...

Time July 10, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 09, 2024
arrow
Feature | Computed Tomography (CT) | By Melinda Taschetta-Millane

In the ever-evolving landscape of medical imaging, computed tomography (CT) stands out as a cornerstone technology ...

Time July 08, 2024
arrow
Feature | Radiology Business

ITN conducts a bi-monthly survey to its readers on a variety of topics, which is used to create the Last Read, a unique ...

Time July 08, 2024
arrow
Subscribe Now